158 related articles for article (PubMed ID: 21923175)
1. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.
van der Stelt M; Cals J; Broeders-Josten S; Cottney J; van der Doelen AA; Hermkens M; de Kimpe V; King A; Klomp J; Oosterom J; Pols-de Rooij I; de Roos J; van Tilborg M; Boyce S; Baker J
J Med Chem; 2011 Oct; 54(20):7350-62. PubMed ID: 21923175
[TBL] [Abstract][Full Text] [Related]
2. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
4. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.
Naguib M; Diaz P; Xu JJ; Astruc-Diaz F; Craig S; Vivas-Mejia P; Brown DL
Br J Pharmacol; 2008 Dec; 155(7):1104-16. PubMed ID: 18846037
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
7. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
9. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
[TBL] [Abstract][Full Text] [Related]
10. Mastering tricyclic ring systems for desirable functional cannabinoid activity.
Petrov RR; Knight L; Chen SR; Wager-Miller J; McDaniel SW; Diaz F; Barth F; Pan HL; Mackie K; Cavasotto CN; Diaz P
Eur J Med Chem; 2013 Nov; 69():881-907. PubMed ID: 24125850
[TBL] [Abstract][Full Text] [Related]
11. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
Watson C; Owen DR; Harding D; Kon-I K; Lewis ML; Mason HJ; Matsumizu M; Mukaiyama T; Rodriguez-Lens M; Shima A; Takeuchi M; Tran I; Young T
Bioorg Med Chem Lett; 2011 Jul; 21(14):4284-7. PubMed ID: 21669533
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.
Giblin GM; O'Shaughnessy CT; Naylor A; Mitchell WL; Eatherton AJ; Slingsby BP; Rawlings DA; Goldsmith P; Brown AJ; Haslam CP; Clayton NM; Wilson AW; Chessell IP; Wittington AR; Green R
J Med Chem; 2007 May; 50(11):2597-600. PubMed ID: 17477516
[TBL] [Abstract][Full Text] [Related]
13. Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.
Bartolozzi A; Cirillo PF; Berry AK; Hickey ER; Thomson DS; Wu L; Zindell R; Albrecht C; Ceci A; Gemkow MJ; Nagaraja NV; Romig H; Sauer A; Riether D
Bioorg Med Chem Lett; 2015 Feb; 25(3):587-92. PubMed ID: 25575658
[TBL] [Abstract][Full Text] [Related]
14. First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain.
Mladenova G; Annedi SC; Ramnauth J; Maddaford SP; Rakhit S; Andrews JS; Zhang D; Porreca F
J Med Chem; 2012 Apr; 55(7):3488-501. PubMed ID: 22420844
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.
Pajouhesh H; Feng ZP; Zhang L; Pajouhesh H; Jiang X; Hendricson A; Dong H; Tringham E; Ding Y; Vanderah TW; Porreca F; Belardetti F; Zamponi GW; Mitscher LA; Snutch TP
Bioorg Med Chem Lett; 2012 Jun; 22(12):4153-8. PubMed ID: 22579422
[TBL] [Abstract][Full Text] [Related]
16. 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.
Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Varani K; Targa M; Vincenzi F; Borea PA; Aghazadeh Tabrizi M
J Med Chem; 2012 Jul; 55(14):6608-23. PubMed ID: 22738271
[TBL] [Abstract][Full Text] [Related]
17. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
18. Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
Harnett JJ; Dolo C; Viossat I; Auger F; Ferrandis E; Bigg D; Auguet M; Auvin S; Chabrier PE
Bioorg Med Chem Lett; 2015 Jan; 25(1):88-91. PubMed ID: 25466197
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
20. Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters.
Zindell R; Walker ER; Scott J; Amouzegh P; Wu L; Ermann M; Thomson D; Fisher MB; Fullenwider CL; Grbic H; Kaplita P; Linehan B; Patel M; Patel M; Löbbe S; Block S; Albrecht C; Gemkow MJ; Shih DT; Riether D
Bioorg Med Chem Lett; 2011 Jul; 21(14):4276-80. PubMed ID: 21689933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
